August holds 5 big FDA decisions; Spark weighs installment payments for blindness therapy;

> The FDA this month is expected to announce big approval decisions for companies including Bristol-Myers Squibb ($BMY), Alkermes ($ALKS) and Amgen ($AMGN). Report

> In Q2, Endo's ($ENDP) branded pharma revenue increased 27%, while generics posted a 24% top-line rise. Release

> Spark Therapeutics ($ONCE) is weighing installment payments for a gene therapy candidate for blindness that analysts predict will be pricey. Report

> Kwang Dong Pharma will market Orexigen's ($OREX) weight loss drug, Contrave, in South Korea. Report

> Shire ($SHPG) has launched the second annual Excellence in ADHD Patient Group Awards. Release

> People on extended-interval prophylaxis regimens with new, long-acting Biogen ($BIIB) hemophilia therapy Eloctate experienced low bleeding rates in a Phase III study. Release

> GlaxoSmithKline ($GSK) is rolling out a tooth sensitivity awareness campaign for Sensodyne toothpaste in India. Report

And Finally... A U.K. company is preparing to launch the first traditional Chinese medicine approved in the country. Report (sub. req.)

Suggested Articles

Rather than accept a filing based on phase 1/2 data, the FDA wants Novartis to run a phase 3 for a market-expanding version of gene therapy Zolgensma.

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Call it a fall sports bounce. TV ad spending bumped up in August with the partial return of professional sports, and that included pharma buyers.